AllDocs -> cancers

Osteopontin Identified as Lead Marker of Colon Cancer Progression, Using Pooled Sample Expression Profiling Deepak Agrawal, Tingan Chen, Rosalyn Irby, John Quackenbush, Ann F. Chambers, Marianna Szabo, Alan Cantor, Domenico Coppola, Timothy J. Yeatman Background: New tumor markers and markers of tumor progression are needed for improved staging and for better assessment of treatment of many cancers. Gene expression profiling techniques offer the opportunity to discover such markers. We investigated the feasibility of sample pooling strategy in combination with a novel analysis algorithm to identify markers. Methods: Total RNA from human colon tumors (n = 60) of multiple stages (adenomas; cancers with modified Astler Collier stages B, C, and D; and liver metas- tases) were pooled within stages and compared with pooled normal mucosal specimens (n = ...

175 Ninth Avenue. New York, NY 10011 212.627.7451 www.CCAlliance.org the voice of survivors Colon Cancer Connections: Peer Support for Survivors and Caregivers CCA’s Website www.CCAlliance.org If you or someone you love is battling CRC, we urge you to find a way to get to our website.We realize that many people do not have computers in their homes. Free Internet time is often avail- able through public libraries, senior centers and public schools. Friends and relatives may have the ability to log on, and often hospital social workers may be able to work with patients to pro- vide internet access. CCA offers a range of information, publica- tions and programs through our website.A subset is available by phone and mail. Some support services you will find on the website include: ? Personal stories The Colon Cancer Alliance website ...

USC CLINICAL GENETICS UNDERSTANDING YOUR FAMILY HISTORY OF COLON CANCER UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE DEPARTMENT OF OBSTETRICS AND GYNECOLOGY DIVISION OF GENETICS Location: Two Medical Park Suite 301 Columbia, SC 29203 Phone: 803-779-4928 ext. 228 Toll free in SC: 800-544-9866 Fax: 803-434-6852 (laboratory) Fax: 803-434-4596 (genetic counselors) E-mail: uscgenetics@medpark.sc.edu Web: www.med.sc.edu/uscgenetics 13 C olorectal cancer is the third most common cancer diagnosed in the United States. In 2000 alone, an estimated 135,000 new cases were diagnosed. The chance that a person will develop colorectal cancer in his or her lifetime approaches 6%. Family History: Most cases of colorectal cancer occur by chance in individ- ...

1.) REUTERSHEALTH A. Prostate Cancer therapy not tied to colon cancer ," by Megan Rauscher (Reuters Health, March 29, 2004). http://www.reutershealth.com/archive/2004/03/29/eline/links/20040329elin019.html B. "Gene works with pesticides to up Parkinson's risk" (Reuters Health, Apr. 2, 2004). http://www.reutershealth.com/archive/2004/04/01/eline/links/20040401elin022.html 2.) EUREKALERT A. "Soy consumption could help prevent prostate cancer and male pattern baldness," (Eurekalert [American Association for the Advancement of Science], March 29, 2004). http://www.eurekalert.org/pub_releases/2004-03/chmc-scc032904.php B. "Black men less likely to be treated for aggressive prostate cancer , UMHS study finds," (Eurekalert [American Association for the Advancement of Science], March 29, 2004). http://www.eurekalert.org/pub_releases/2004-03/uomh-bml032904.php ...

Abstract. We have shown that genistein, a major component of soy, has anti- colon cancer effects in vitro . These effects are attainable at high concentrations that are difficult to achieve in the serum. The purpose of this study was to enhance the activity of genistein against colon cancer cells by coupling it to 17.1A. The monoclonal antibody 17.1A recognizes an epithelial membrane antigen that is overexpressed in colon cancer . Synthesis of Gen-17.1A was achieved by photo- chemical conjugation using sulfa-SANPAH. Its purity was evaluated by SDS-PAGE. Binding of Gen-17.1A to SW- 620 and HT-29 cells was shown using flow cytometry. Internalization was demonstrated by FITC-labeling. Gen- 17.1A induced apoptosis in colon cancer cells as evidenced by the acridine orange/ethidium bromide staining method. Gen-17.1A significantly inhibited colon cancer cell growth ...

Abstract. The chemoprevention of colon cancer , the second leading cause of cancer -related deaths in the United States, has been pursued actively during the last two decades. Methodological problems and those stemming from the available agents per se have constrained this difficult task; to some extent, these problems persist to date. That NSAIDs decrease the incidence of and mortality from colon cancer has been a major advance in chemoprevention. These compounds are, however, limited by their significant side effects. NO-releasing NSAIDs (NO-NSAIDs) are a novel class of compounds, synthesized to overcome the limitations of NSAIDs. In general, they appear safer and much more effective than their traditional counterparts. We review their structural features, metabolism and pharmacological actions. In vitro and in vivo studies indicate that they are much more effective than ...

Abstract. MSH2 and MLH1 are proteins involved in DNA reparation. They are mutated in some forms of colon cancer , i.e. hereditary non-polyposis carcinomas and a subset of sporadic carcinomas. We have studied the expression of MSH2 and MLH1 in a retrospective series of 225 colorectal carcinomas by immunohistochemistry. The results were compared to molecular tests of microsatellite instability using amplification by PCR of BAT-25 and BAT-26 repeated sequences and to histoclinical data. Positivity of both proteins was never associated with MSI phenotype. MSH2 and/or MLH1 negative tumors were frequently tumors of the proximal colon ; in this subpopulation or proximal tumors, MSH2 and/or MLH1 negativity was associated with a longer disease- free survival. Introduction Several types of genetic alterations are found in human cancers. One of these is characterized by an instability of ...

Abstract. The current chemotherapeutic modalities for advanced colorectal cancer are limited. DNA-platinating drugs such as cisplatin have poor efficacy against this malignancy. The aim of this study was to identify genes that render survival advantage after cisplatin treatment in metastatic colon cancer . Cell lines SW480 (primary colon cancer ) and SW620 (metastatic lesion from the same patient) were obtained from ATCC. Apoptosis was measured by FACS analysis of cisplatin-treated (0.01-10 µ g/ml) and untreated cells. Simultaneous analysis of ~1200 cDNAs was performed by microarray technique on untreated and treated cells from lines. Microarray results were confirmed by RT-PCR. The SW620 cell line was more resistant to apoptosis induced by cisplatin. Western blot analysis revealed equal expression of pro-caspases 3, 8, and 9 in both cell lines. Microarray analysis ...

Abstract. Telomerase activation, a cardinal requirement for immortalization, is a crucial step in the development of malignancy and requires the induction of the catalytic component, human telomerase reverse transcriptase (hTERT), encoded by the hTERT gene. By reverse transcription-PCR, using primers within the reverse transcriptase domain of hTERT, we investigated telomerase messenger in 8 adenomatous and 9 dysplastic polyps, and in 32 paired cancer -normal mucosa specimens, one liver and one spleen metastasis from patients resected for sporadic colorectal cancer . Telomerase messenger was absent or very low in normal mucosa and in adenomatous polyps. Dysplastic polyps and adenocarcinoma samples showed hTERT mRNA, with higher levels in cancer tissues compared to dysplastic lesions. A high telomerase messenger level was shown to be associated with late-staged cancers and with metastasis; ...

MC2937-72 Average risk patient, no risk factors for colorectal cancer except age = 50 yo Single 1st-degree * relative with colorectal cancer or tubular adenoma dx = age 60, 1,3 or two 2nd-degree * relatives diagnosed with colorectal cancer 1 Single 1 st -degree relative with colorectal cancer or tubular adenoma <60 yo or in two 1 st -degree relatives of any age If age = 80 at the time of colon screening Inflammatory bowel disease, chronic UC or Crohn’s disease Mayo Clinic in Scottsdale – Guidelines for Colon Cancer Screening and Surveillance by Colonoscopy Begin screening at age 50. Begin screening at age 40. 1,3 Age 40, or 10 years before the youngest ...

Spring 2002 Presorted Standard U.S. Postage PAID Tacoma, WA Permit No. 1066 Cancer of the colon and rectum can be deadly. It can strike anyone. But the good news is that colorectal cancer can be prevented. The key is to find and remove tumors before they turn cancerous. Beginning at age 50, testing for colorectal cancer includes one of the following: I Sigmoidoscopy—every five years. I Colonoscopy—every 10 years. I Double-contrast barium enema—every five to 10 years. Each year your doctor should also give you a test to do at home that checks for blood in the bowel movement. This is called the fecal occult blood test, or stool test. These tests are the most current screening guidelines of the American Cancer Society and are recommended for members of Santa Barbara Regional Health Authority. If you are 50 or older, ...

NP Poster 138 Colon Cancer Screening: knowledge, Attitudes, and Behavior Among African- American Women Jennifer Swedmark, ARNP MSN, Tallahassee, FL (email directed to dfrank@nursing.fsu.edu ); D. Frank, ARNP, PhD, Professor, Florida Sate University (FSU) Tallahassee, FL, L Grubbs, ARNP PhD, FSU PURPOSE: The purpose of this research was to investigate the frequency of colorectal cancer screening African-American women aged 50 and older who are in the high risk category for developing colorectal cancer and polyps. Additionally, their beliefs and attitudes were examined through the guidance of the Health Belief Model to aid in the prediction of screening utilization. METHODOLOGY: This randomized study used a descriptive/correlative, non-experimental survey approach. Participants were recruited through faith-based organizations in 4 quadrants of a north Florida city and were mailed ...

KIMBA ROXBY DOWNS (M) COOBER PEDY (DC) UNINCORP. FAR NORTH UNINCORP. FLINDERS RANGES ROBE BERRI CLARE HAWKER CEDUNA TANUNDA WHYALLA MENINGIE WILLUNGA MAITLAND PORT PIRIE BORDERTOWN PORT LINCOLN PETERBOROUGH PORT AUGUSTA MOUNT GAMBIER PORT BROUGHTON 0 100 200 50 Kms Colon Cancer Mortality in South Australia, 1991-2000 by Statistical Local Areas GAWLER GLENELG MODBURY WILLUNGA ADELAIDE WOODVILLE ELIZABETH MOUNT BARKER BEDFORD PARK NOARLUNGA CENTRE Annual Mortality/100,000 0 - 10 11 - 15 16 - 20 21 - 30 Towns Statistical Local Areas Produced by: Data Analysis and Consulting Unit, Information Management Services, and Epidemiology Branch, Department of Human Services. Data Sources: Cancer ...

KIMBA ROXBY DOWNS (M) COOBER PEDY (DC) UNINCORP. FAR NORTH UNINCORP. FLINDERS RANGES ROBE BERRI CLARE HAWKER CEDUNA TANUNDA WHYALLA MENINGIE WILLUNGA MAITLAND PORT PIRIE BORDERTOWN PORT LINCOLN PETERBOROUGH PORT AUGUSTA MOUNT GAMBIER PORT BROUGHTON 0 100 200 50 Kms Incidence of Colon Cancer in South Australia, 1991-2000 by Statistical Local Areas GAWLER GLENELG MODBURY WILLUNGA ADELAIDE WOODVILLE ELIZABETH MOUNT BARKER BEDFORD PARK NOARLUNGA CENTRE Annual Incidence/100,000 0 - 20 21 - 30 31 - 50 51 - 70 Towns Statistical Local Areas Produced by: Data Analysis and Consulting Unit, Information Management Services, and Epidemiology Branch, Department of Human Services. Data Sources: Cancer ...

Cancer of the Colon and Rectum (Colorectal Cancer ) DEFINITION The colon (large intestine) and rectum make up the final segment of the digestive tract. It is the lower four to five feet of the intestine that travels around the borders of your abdominal area. The rectum is the last four to five inches at the end of the colon . Cancer can develop anywhere along the digestive tract. Cancer of the colon and rectum is called colorectal cancer . Colorectal cancer is potentially one of the most curable cancers if detected early. INCIDENCE • Second leading cause of death from cancer and it affects men and women equally • 160,000 new cases are diagnosed each year in the United States. RISK FACTORS • Age over 40 • Family history of colon cancer or multiple polyps in a parent, sibling or other family member • History of colon , ...